Skip to content

A Tailored, Web-Based Self-Management Program to Treat Pain in Chronic Pancreatitis

A Tailored, Web-Based Self-Management Program to Treat Pain in Chronic Pancreatitis

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT07223554
Enrollment
31
Registered
2025-11-03
Start date
2025-12-04
Completion date
2026-04-28
Last updated
2026-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pancreatitis

Keywords

Behavioral intervention, Self-management, Pain

Brief summary

This research study aims to evaluate the feasibility and acceptability of a web-based, self-guided, disease-specific self-management program tailored to individual health status profiles for patients with painful chronic pancreatitis.

Detailed description

This is a single center, prospective, open-label, pilot trial of 30 patients with painful chronic pancreatitis (CP). Participants will be assigned to a 12-week web-based, self-management program known as PainGuide that has been adapted to CP. Participants will receive specific instruction to complete one module a week over the first 4 weeks. Next, participants will receive weekly tailored messaging for the last 8 weeks using symptom scores from baseline assessments and will be asked to complete modules that best address participants symptoms. Participants will complete online surveys at baseline, 4 weeks, 8 weeks, and 12 weeks, and will be interviewed at the end of program to understand participants perceptions on the intervention.

Interventions

BEHAVIORALWeb-based self--management program

Participants in this study will be granted access to the adapted website after participants complete baseline questionnaires. All participants will be encouraged to engage with all the sections of the website. From week 1 to 4, participants will receive a single standardized guidance to complete one module a week on generic pain modules. From weeks 5 to 12, participants will receive weekly tailored messaging that will direct participants to specific modules based on individual survey scores from the baseline assessments.

Sponsors

University of Michigan
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Physician diagnosis of chronic pancreatitis. * Abdominal pain for ≥ 3 months and of intensity rated at least 4 or higher on a 0-10 Numeric Rating Scale at least once in the last month. * Access to an Internet-connected device (e.g. computer or phone).

Exclusion criteria

* Unable to speak or read English as the web-based program is currently in English language only. * Incarcerated individuals. * Currently receiving chemotherapy. * Suspected or diagnosed pancreatic cancer. * Currently receiving psychotherapy or cognitive behavioral therapy. * Serious visual difficulties that would limit completing the web-based program. * Substantial cognitive impairment or mental illness that would prevent providing informed consent and completion of questionnaires. * Any other condition, which in the opinion of the investigator would impede compliance or hinder the completion of the study. * Actively enrolled in another clinical trial for chronic pancreatitis.

Design outcomes

Primary

MeasureTime frameDescription
Proportion of enrolled participants that log in at least once during weeks 1-4 and at least once to the recommended modules during weeks 5-12.12 weeksThis number is used to determine adherence to the intervention.
Proportion of participants with an average item score of ≥4 out of 5 on the Acceptability of Healthcare Interventions Questionnaire12 weeksThis is a validated 8-item questionnaire that assesses acceptability using a 5-point Likert scale rated 1-5.

Secondary

MeasureTime frameDescription
Proportion of participants approached that enroll in the study.Approximately 1 year (during recruitment period)This number is used to determine enrollment feasibility to the web-based program in patients with painful CP.
Proportion of enrolled participants that log in at least once during the 12-week program12 weeksThis number is used to determine minimal adherence to the web-based program in patients with painful CP.
Proportion of enrolled participants that log in at least once a week during weeks 1-4 and at least once a week to the recommended modules during weeks 5-12.12 weeksThis number is used to determine maximal adherence to the web-based program in patients with painful CP.
Number of logins per participant during the 12-week intervention12 weeksThis number is used to determine engagement with the web-based program in patients with painful CP.
Proportion of fully completed questionnaires by the total number given to participants12 weeksThis number is used to assess the feasibility of data collection procedures.
Proportion of participants who scores the general acceptability item on the acceptability scale ≥4 out of 512 weeksThis is a validated 8-item questionnaire that assesses acceptability using a 5-point Likert scale rated 1-5.
Proportion of participants that feel the web-based program is easy and intuitive to use based on a usability score > 68 on the System Usability Scale (SUS)12 weeksThis is a validated 10-item questionnaire that measures the perceived usability of a system focusing on ease of use, efficiency, and overall satisfaction. Participants score from 1 (strongly disagree) to 5 (strongly agree). To calculate the SUS score, respondents' ratings are adjusted: subtract 1 from the score for odd-numbered items and subtract each score from 5 for even-numbered items. The adjusted scores are then summed and multiplied by 2.5, yielding a total score ranging from 0 to 100. Generally, a SUS score above 68 indicates above-average usability, though this benchmark can vary with different systems.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORJorge Machicado, MD, MPH

University of Michigan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 2, 2026